Macquarie Group Ltd. grew its holdings in shares of Nevro Corp (NYSE:NVRO) by 21.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 36,548 shares of the medical equipment provider’s stock after purchasing an additional 6,437 shares during the period. Macquarie Group Ltd. owned about 0.12% of Nevro worth $2,918,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. SG Americas Securities LLC acquired a new stake in shares of Nevro during the 1st quarter worth approximately $208,000. Victory Capital Management Inc. boosted its position in shares of Nevro by 2,245.0% during the 1st quarter. Victory Capital Management Inc. now owns 2,345 shares of the medical equipment provider’s stock worth $203,000 after acquiring an additional 2,245 shares in the last quarter. Prudential Financial Inc. acquired a new stake in shares of Nevro during the 1st quarter worth approximately $252,000. Swiss National Bank boosted its position in shares of Nevro by 2.5% during the 1st quarter. Swiss National Bank now owns 41,100 shares of the medical equipment provider’s stock worth $3,562,000 after acquiring an additional 1,000 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its position in shares of Nevro by 5.5% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 138,126 shares of the medical equipment provider’s stock worth $11,972,000 after acquiring an additional 7,139 shares in the last quarter.

NVRO has been the topic of several analyst reports. Canaccord Genuity reduced their price target on shares of Nevro from $102.00 to $83.00 and set a “buy” rating on the stock in a research report on Monday, July 16th. Bank of America reduced their price target on shares of Nevro from $102.00 to $77.00 and set a “buy” rating on the stock in a research report on Tuesday, July 17th. BMO Capital Markets reduced their price target on shares of Nevro from $80.00 to $76.00 and set an “outperform” rating on the stock in a research report on Monday, August 6th. ValuEngine upgraded shares of Nevro from a “strong sell” rating to a “sell” rating in a research report on Tuesday, August 7th. Finally, Morgan Stanley lowered shares of Nevro from an “overweight” rating to an “equal weight” rating and set a $95.00 price target on the stock. in a research report on Monday, July 2nd. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $81.89.

Shares of NYSE:NVRO opened at $57.43 on Friday. The company has a market capitalization of $1.78 billion, a P/E ratio of -45.94 and a beta of -0.71. The company has a quick ratio of 6.29, a current ratio of 8.06 and a debt-to-equity ratio of 0.61. Nevro Corp has a one year low of $35.41 and a one year high of $94.34.

Nevro (NYSE:NVRO) last issued its quarterly earnings data on Thursday, August 2nd. The medical equipment provider reported ($0.35) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.04). The company had revenue of $96.10 million during the quarter, compared to the consensus estimate of $96.10 million. Nevro had a negative net margin of 10.68% and a negative return on equity of 15.84%. Nevro’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same period in the previous year, the company earned ($0.40) EPS. research analysts forecast that Nevro Corp will post -1.42 earnings per share for the current fiscal year.

About Nevro

Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Recommended Story: How to Invest in Marijuana Stocks

Want to see what other hedge funds are holding NVRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nevro Corp (NYSE:NVRO).

Institutional Ownership by Quarter for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.